FDA tells Purell to stop claiming it can prevent flu

Marketing campaign also claims product can prevent ebola spread


The Food and Drug Administration (FDA) told the maker of Purell to discontinue marketing campaigns that includes claims for avoiding flu and ebola, according to an article on The New York Times website.

The campaigns also claim the product can prevent spread of MRSA and norovirus.

The FDA told Gojo Industries that its claims that Purell could reduce the potential for infection or prevent illnesses violated the Federal Food, Drug and Cosmetic Act. 

The agency said it was reclassifying Purell as an unapproved drug, rather than an over-the-counter product.

Read the article.



February 10, 2020


Topic Area: Infection Control

Recent Posts

Healthcare Security: To Arm Or Not To Arm?

Deciding whether or not to hire armed security personnel requires that managers understand a range of critical considerations.

False Alarm at Kansas Hospital Highlights Importance of Alarm System Reliability

After a two-hour search of the hospital and nearby medical facilities, no threat was found.

Integrated Oncology Network Caught Up in Data Breach

The network first learned of the incident on April 11, 2025.

ISSA Introduces Healthcare Platform to Advance Safer, Cleaner Patient Environments

This new resource integrates training, research and cross-sector collaboration to raise care standards and improve patient outcomes.

Third-Party Tracking Settlement is a Compliance Wake-Up Call for Healthcare Facilities Managers

Mount Sinai Health System agrees to a $5.3 million settlement to resolve claims it improperly shared patient data with Facebook through tracking tools.

 
 


FREE Newsletter Signup Form

News & Updates | Webcast Alerts
Building Technologies | & More!

 
 
 


All fields are required. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.